Background: Moyamoya disease (MMD) is an idiopathic steno-occlusive cerebrovascular disease
pendent risk factor for recurrence of arterial ischemic stroke in children. 5 Thus, MMD is an important cause of stroke especially for children. Moreover, MMD is a progressive disease, and there are no effective treatments for preventing the narrowing of the intracranial arteries. Surgery using an extracranial-intracranial bypass can be used as a treatment option, 6, 7 but it is a heavy burden to carry, particularly for children.
Two previous genome-wide linkage studies that mainly involved affected siblings or relative pairs identified two loci for MMD at 3p24.2-p26 8 and 8q23. 9 Another candidate locus at 17q25 was proposed from chromosome-wide linkage analyses. 10 However, no disease-causing gene has yet been identified. The different loci identified by these linkage studies most likely represent locus heterogeneity. In the context of genetic heterogeneity, linkage analyses using affected siblings or relative pairs have only limited statistical power and are often confounded by false-negative results. 11 Alternatively, parametric analyses using extended pedigrees of Mendelian traits provide us more chances to identify a disease-causing gene. In the present study, we selectively recruited families of Ն3 generations without consanguinity, in which an autosomal dominant mode of inheritance can be rationally assumed. Genome-wide parametric analyses with the affected member-only method provided significant evidence of a major gene locus for autosomal dominant MMD in the telomeric region of chromosome 17q. Identification of a gene responsible for MMD would lead to understanding of the disease pathogenesis, thereby enabling the development of new therapeutic options to prevent disease progression.
METHODS Clinical evaluation.
According to the official diagnostic criteria proposed in 1997 by the Research Committee on the Spontaneous Occlusion of the Circle of Willis of the Ministry of Health and Welfare, Japan (RCMJ), 12 MMD should be defined as follows: 1) stenoocclusive lesions around the terminal portions of the ICAs including the proximal portions of the anterior cerebral arteries (ACAs) and middle cerebral arteries (MCAs); 2) moyamoya vessels at the base of the brain illustrated by abnormal vascular networks on conventional angiography or more than two flow voids in the basal ganglia on MRI; and 3) these findings are present bilaterally. Patients with unilateral involvement of these findings were diagnosed as probable MMD. However, MMD is a progressive disease and its phenotype changes dynamically according to the disease stage. For example, collateral vessels cannot be detected in the early and end stages, 1, 13 and unilateral MMD can progress to bilateral involvement during its follow-up. 14, 15 Therefore, the core spectrum of the diagnostic criteria for MMD is the steno-occlusive lesions around the terminal portion of the ICAs. On the basis of these observations, we analyzed our data under two diagnostic classifications: narrow and broad (table 1) . The narrow classification only included patients with definite MMD according to the RCMJ criteria. For the broad diagnostic classification, we employed modified diagnostic criteria, in which any steno-occlusive lesions around the terminal portions of the ICAs, either unilaterally or bilaterally, were considered to be in the continuum of the MMD phenotype even without findings of moyamoya vessels. The modified diagnostic criteria may be applicable only to those who have a family history of definite MMD. Accordingly, the broad classification contained the following phenotypes: 1) definite MMD; 2) probable MMD (unilateral MMD); and 3) either bilateral or unilateral steno-occlusive lesions around the terminal portion of the ICAs without findings of moyamoya vessels.
The medical records of participants who had already been diagnosed were checked to confirm the diagnosis of MMD. A clinical interview and examinations by MRI and magnetic resonance angiography (MRA) were carried out for all available relatives, and conventional angiography was conducted when necessary. We ascertained the medical his- tory, age, age at onset, age at diagnosis, first sign at onset, course of the disease, treatment option, and associated diseases. Families with moyamoya syndrome, that is, MMD with known causes such as neurofibromatosis type 1 (NF1), protein C deficiency, Down syndrome, or past radiation therapy in the head, were excluded from this study. The present study was approved by the Ethics Committee of the Kyoto University Institutional Review Board and approved written informed consent was obtained from all subjects or their parents if the subjects were children younger than 16 years. An autopsy brain was obtained from II-9 in Family 6 (figure e-1, on the Neurology ® Web site at www.neurology.org), with written informed consent from a family member.
Family pedigrees. As shown in figure e-1 we recruited 15
pedigrees of familial MMD for whom DNA samples were available from Ն3 affected and unaffected individuals. These families had never participated in previous linkage studies. Twelve families (families 1 through 6, 8 through 10, and 13 through 15) were reported in our earlier report, 16 and the family IDs in the present study correspond to those in the previous report (DNA samples were not available from Families 7, 11, and 12). We expanded Family 2, in which Individuals I-2, II-1, II-3, II-6, and III-1 were newly recruited and individual IV-4 had received an initial screening examination by MRI and MRA. The remaining three families were assigned as Families 16 through 18. Under the broad classification, all the families ranged for Ն3 generations from the founders (we assumed the nearest common ancestor of the affected individuals to be the founder), justifying a parametric model as an autosomal dominant transmission. 16 We consistently used a parametric analysis with a dominant model even under the narrow classification, since 12 of the 15 families ranged for Ն3 generations and satisfied a dominant model (Families 8, 17, and 18 would be one or two generational families). We defined an obligatory carrier as a non-founder with affected offspring, if one's phenotype had been confirmed to be normal by MRI and MRA or one was deceased.
The demographic features of the participating pedigrees and pedigree members are shown in table 2. We observed a total of 55 patients (38 women and 17 men) with MMD phenotype under the broad diagnostic classification, of which 53 patients (the other two had been deceased) were finally enrolled in the study. Twenty-five patients showed childhood onset (Ͻ15 years of age). The female and childhood predominances were compatible with the characteristics of MMD in a previous report. 2 Among the 55 patients, 43 (28 women and 15 men) were patients with definite MMD and five were patients with probable MMD (II-2 in Family 1, II-2 in Family 8, II-2 in Family 9, I-2 in Family 10, and II-4 in Family 17). Stenoses around the terminal portion of the ICAs without collateral vessels were found bilaterally in one patient (II-3 in Family 1) and unilaterally in six patients (II-2 in Family 5, II-3 in Family 9, II-2 in Family 10, IV-4 in Family 14, I-2 in Family 17, and III-3 in Family 18). Observations of patients with various phenotypes (unilateral or bilateral, or with or without collateral vessels) in a single family justified our assumption that these phenotypes were within the continuum of MMD phenotypes. This assumption is also supported by the findings that two pairs of identical twins (IV-3 and IV-4 in Family 14 and II-3 and II-4 in Family 17) showed qualitative differences in their disease phenotypes. We observed the skipping of a generation phenomenon and assumed 13 obligatory carriers, of whom five (II-3 in Family 3, II-2 in Family 13, III-9 in Family 14, and III-3 and III-7 in Family 15) were confirmed not to have any abnormal findings on MRI and MRA, indicating incomplete penetrance of MMD. In addition, we observed rapid disease emergence in Individual III-3 in family 18, a 37-year-old woman without any vascular risk factors, who had no occlusive lesions around the terminal portions of the ICAs in 2005 at the start of her participation in the study but had developed lesions 1 year later in 2006, suggesting age-dependent penetrance of the disease.
Genotyping. Genomic DNA was extracted from blood samples from living patients and the autopsy brain from a deceased participant (II-9 in Family 6) using a QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden, Germany). For genotyping in the genome-wide linkage study, an ABI Prism Linkage Mapping Set (Version 2; Applied Biosystems, Foster City, CA) with 382 markers for 22 autosomes and 18 markers for the X chromosome with more than 75% heterozygosity was used at about 10-cM resolution as described previously. 17 Briefly, genomic DNA extracted from peripheral blood was amplified by PCR with fluorescently labeled markers, and the PCR products were analyzed by an ABI Prism 3100 Avant Genetic Analyzer (Applied Biosystems) using the Genescan program. Fine mapping markers were designed according to information from the Marshfield genetic map (http://research.marshfieldclinic.org/genetics/). We used 
Type of onset
Childhood onset (Ͻ15 y) 25
Adult onset (Ն15 y) 15
Asymptomatic 13
Unknown 2
Symptom at onset
Ischemic stroke 29
Hemorrhagic stroke 6
Epilepsy 4
Headache 1
Asymptomatic 13
Unknown 2 single nucleotide polymorphism (SNP) markers with minor allele frequencies of Ͼ10% if we could not obtain microsatellite markers. Genotyping of SNP markers was performed using a PCR-restriction fragment length polymorphism (RFLP) method as previously described. 18 A total of 17 markers were genotyped at 12.5-Mb intervals at the 17q25-qter linkage region. The marker locations were obtained from the uniSTS reference physical map (http://www.ncbi.nlm.nih.gov/genome/ sts/). Merlin software 19 (http://www.sph.umich.edu/csg/ abecasis/Merlin) was used to detect genotyping errors and Mendelian inconsistency. When genotyping resulted in no calls or an ambiguous call, the genotype was set to "unknown." Overall successful call rate was 99.8%.
Linkage and haplotype analyses. We conducted a parametric linkage analysis assuming a dominant model. An affected member-only analysis was employed on the basis of observations of incomplete and age-dependent penetrance of MMD. In the analysis, we assigned an affected individual as either one whose phenotype was clinically diagnosed by either the narrow or broad classification or an obligatory carrier. The rationale for the assumption that obligatory carriers should be treated as affected was the low penetrance and low disease allele frequency. To increase the accuracy of haplotype estimation in affected individuals, we included unaffected individuals and non-founder spouses. The phenotype of unaffected related individuals in the pedigrees was assigned as unknown, while non-founder spouses were assigned as unaffected. On the basis of the observed prevalence of 3.16 per 100,000 persons, 2 the disease allele frequency should be set at 0.0000158, but we set it more conservatively at 0.0001 due to the increasing number of asymptomatic patients who have recently been diagnosed by MRI and MRA. 20 We assumed a phenocopy frequency of 0.00001. Population allele frequencies for each microsatellite marker were estimated from all the unrelated founders using the Merlin software, 19 with the exception of the X chromosome. For the X chromosome, we assigned equal portions for individual alleles. A two-point linkage analysis was performed using the MLINK program of LINKAGE version 5.2 (http:// linkage.rockefeller.edu/soft/linkage). 21 Multipoint analyses for autosomes and X chromosome were run with a onetailed probability value using GENEHUNTER version 2.0 (http://www.broad.mit.edu/ftp/distribution/software/genehunter/). 22 Since locus heterogeneity could be associated with MMD, we obtained both logarithm of odds (lod) and heterogeneity-adjusted logarithm of odds (HLOD) scores. 22 We employed a multipoint lod score of Ͼ3.6 as the threshold for genome-wide significance, and a lod score of Ͼ3.3 for the two-point analysis. 22 Haplotypes were constructed with the GENEHUNTER program. To avoid mis-specification of the inheritance pattern, we confirmed our results by nonparametric analysis. Nonparametric linkage (NPL) score was obtained using the GENEHUNTER program.
Mutation analysis of candidate genes. The 3.5-Mb candidate interval on chromosome 17q25-qter contains 94 annotated genes, of which 28 are predicted genes of unknown function (NCBI Human Genome Resources). There appear to be several putative candidate genes around the interval, which included BAI1-associated protein 2 (BAIAP2), tissue inhibitor metalloproteinase-2 (TIMP2), ras-related C3 botulinum toxin substrate 3 (RAC3), an important regulator of cell growth and cytoskeletal reorganization, or RAB40B, member of ras oncogene family (RAB40B). These four candidate genes were directly sequenced for a proband of five families (Families 1, 2, 5, 14, and 15 ) including coding exons, exonintron boundaries, and 3= untranslated regions in the same way as described previously. 23 Any polymorphic sites identified through our sequencing were searched for SNP database (dbSNP, http://www.ncbi.nlm.nih.gov/SNP/index.html). When a minor allele frequency of a variant has not been determined yet in the database, genotyping was performed in 32 control subjects using PCR-RFLP method as described previously. 18 Variants with a minor allele frequency of Ͼ1% were considered not to be associated with autosomal dominant MMD because it is a relatively rare disease and is likely to be caused by a mutation. As Ϫ418GϾC in TIMP2 gene on chromosome 17q25 has been shown to be associated with familial MMD in a recent report, 24 we genotyped Ϫ418GϾC for the probands of families using PCR-RFLP method.
RESULTS
The results of genome-wide screening are shown in figure 1. Significant evidence of linkage was only observed on chromosome 17q25-qter, with maximum multipoint lod scores of 5.92 (HLOD score ϭ 5.92) under the narrow classification and 7.33 (HLOD score ϭ 7.33) under the broad classification at D17S928. No other regions showed genome-wide lod scores of Ͼ3.6. Two-point lod scores of 4.23 and 4.45 under the narrow classification (5.25 and 5.48 under the broad classification) with a recombination fraction of 0.05 were obtained at two nearby genome-wide screening markers, D17S784 and D17S928 (table e-1). Both the twopoint and multipoint lod scores were linked to the locus in all families, with the exception of Family 14 (data not shown). Results of non-parametric analysis showed practically same result, with only a prominent peak at chromosome 17q25 with a maximum NPL score of 4.51 under the narrow classification (5.51 under the broad classification) at D17S928 (data not shown). Taken together, we considered 17q25-qter as a major genetic locus for MMD with an autosomal dominant mode of inheritance.
To narrow down the genetic locus, we conducted fine mapping of the 17q25-qter linkage region at an average resolution of 0.8 Mb, which gave a maximum multipoint lod score of 6.57 (p ϭ 0.000021) under the narrow classification and 8.07 (p ϭ 0.0000034) under the broad classification at D17S704 (figure 2). A maximum HLOD score of 6.81 under the narrow classification and 8.11 under the broad classification was observed at the same marker. Both the lod and HLOD scores decreased sharply at D17S1806. Sensitivity analyses using various sets of parameter combinations, i.e., the disease allele frequencies (0.0001 or 0.00001) and phenocopy frequencies (0.001, 0.0001, or 0.00001) for either narrow classification or broad classification did not alter either lod or HLOD scores more than 1% (data not shown). As shown in figure e-1, all affected individuals in each family shared a disease haplotype, with the exception of Family 14. Family 14 failed to show a common haplotype in the affected family members, suggesting the possible involvement of locus heterogeneity. Haplotype analysis with fine mapping revealed an obligate recombination between markers D17S1806 and D17S784 in Individual III-2 of Family 2 (figure e-1), which defined the critical MMD gene location within a 3.5-Mb region from D17S1806 to the end of chromosome 17q (uniSTS reference physical map).
The MMD locus at 17q25 reported by Yamauchi et al. spans from D17S785 to D17S836, 10 which lies 1.5-Mb centromeric to D17S1806 of the present locus, suggesting the possibility that their locus may not be identical to our locus. On the other hand, maximum lod and HLOD scores within MMD locus at 3p24-p26.1 8 were Ϫ8.95 and 0.24 under the narrow classification, and Ϫ9.04 and 0.30 under the broad classification. As for MMD locus at 8q23, 9 maximum lod and HLOD scores were Ϫ4.18 and 0.15 under the narrow classification, and Ϫ2.99 and 0.42 under the broad classification. These two loci satisfied the linkage exclusion criteria (lod ϽϪ2.0).
We sequenced four candidate genes (BAIAP2, TIMP2, RAC3, and RAB40B) and identified a total of 37 variants, of which four cause amino acid substitution (data not shown). However, all the nonsynonymous variants were found in the database and their minor allele frequencies were above 1%. A Figure 1 Multipoint parametric lod and heterogeneity-adjusted logarithm of odds scores in the genome-wide screening for familial moyamoya disease (MMD) under the narrow diagnostic classification, in which only patients with definite MMD are assigned as affected, and under the broad diagnostic classification, in which patients with unilateral or bilateral steno-occlusive lesions around the terminal portion of internal carotid arteries including definite MMD and unilateral MMD are designated as affected
The dotted line shows the cutoff for a lod score of Ͼ3.6.
promoter polymorphism Ϫ418GϾC in TIMP2 gene was not polymorphic in our studied population.
DISCUSSION This study presents compelling evidence that a major locus for autosomal dominant MMD lies in the telomeric region of 17q25. The restriction of employment of pedigrees to multigenerational families, which is compatible with autosomal dominant transmission, justified a genome-wide parametric analysis. To circumvent uncertainty in phenotyping arising through low and age-dependent penetrance, we applied an affected member-only analysis after MRI and MRA screening examinations. We analyzed the data under both a narrow classification, in which only patients with definite MMD were assigned as affected, and a broad classification, in which patients with any steno-occlusive lesions around the terminal portions of the ICAs were designated as affected. With such a conservative approach, the present study succeeded in robustly revealing significant evidence of linkage to chromosome 17q25.3 under both classifications, with maximum multipoint lod scores of 6.57 (HLOD score of 6.81, p ϭ 0.000021) under the narrow classification and 8.07 (HLOD score of 8.11, p ϭ 0.0000034) under the broad classification. Segregation of a disease haplotype in all affected individuals was observed in 14 of the 15 families. An informative crossover defined the candidate interval between D17S1806 and the telomere of 17q, corresponding to a distance of about 3.5 Mb. We selected four candidate genes around the disease locus; however, mutation analysis could not identify any deleterious mutations.
The robust results of our linkage analyses under both the narrow and broad diagnostic classifications in turn suggest that our modified diagnostic criteria in the broad classification can be safely applied for the diagnosis of patients with MMD at least in familial cases. If so, the present study, in turn, indicates that MCA stenosis or MCA occlusion of uncertain causes as well as unilateral MMD may also be considered to be in the spectrum of MMD.
One ambiguity in the present study would be the assignment of the obligatory carriers, since we could not detect any lesions in the spectrum of MMD even with MRI and MRA examinations. One explanation for the absence of stenotic lesions in the obligatory carriers would be agedependent progression of MMD, as observed in III-3 of Family 18.
Our locus is close to the previous reported MMD locus at 17q25, 10 but the two loci might not overlap with each other. At present, further evidence is required to confirm whether these two loci are identical. On the other hand, we failed to replicate the other MMD loci at 3p24-p26.1 8 and 8q23. 9 This failure of replication may be attributable to genetic heterogeneity, since the present study restricted the studied pedigrees to multigenerational families, while the other studies mainly used affected siblings or relative pairs. Isolation of a gene responsible for autosomal dominant MMD in our locus will provide evidence for or against genetic heterogeneity.
We selected four candidate genes on the basis of their biologic functions: BAIAP2, TIMP2, RAC3, and RAB40B. BAIAP2 interacts with brain-specific angiogenesis inhibitor-1 (BAI1), which is an inhibitor of basic fibroblast growth factor (bFGF)-induced angiogenesis. 25 A promoter polymorphism of TIMP2 gene was found to be associated with familial MMD in the Korean population. 24 However, it was not polymorphic in our studied population, although we genotyped only a limited number of population. RAC3 and RAB40B are members of ras oncogene family and important regulators of cell growth and cytoskeletal reorganization. No mutation was identified through the mutation analysis of these candidate genes. Further analyses will be needed.
